We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.89%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.82B
AUM Growth
+$296M
Cap. Flow
+$80.3M
Cap. Flow %
4.42%
Top 10 Hldgs %
36.79%
Holding
155
New
17
Increased
81
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$21.6M
2
HUM icon
Humana
HUM
+$21.3M
3
TDOC icon
Teladoc Health
TDOC
+$18.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$9.38M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$56M
2
AMGN icon
Amgen
AMGN
+$5.81M
3
BIIB icon
Biogen
BIIB
+$5.29M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.16M
5
MGNX icon
MacroGenics
MGNX
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 91.35%
2 Industrials 1.12%
3 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
26
Cencora
COR
$59.5B
$19.9M 1.1%
250,398
+3,636
+1% +$292K
ESPR
27
DELISTED
Esperion Therapeutics
ESPR
$19.9M 1.09%
495,547
+43,575
+10% +$1.95M
FIT
28
DELISTED
Fitbit, Inc. Class A common stock
FIT
$19.4M 1.06%
3,268,934
+50,050
+2% +$304K
INSM icon
29
Insmed
INSM
$23.6B
$19.2M 1.05%
659,434
-149,712
-19% -$3.88M
HCM icon
30
HUTCHMED
HCM
$1.95B
$18.3M 1.01%
598,310
+158,141
+36% +$3.94M
WMGI
31
DELISTED
Wright Medical Group Inc
WMGI
$18M 0.99%
573,595
-104,519
-15% -$3.17M
EVH icon
32
Evolent Health
EVH
$648M
$17.7M 0.97%
1,408,237
+1,362,967
+3,011% +$21.6M
ALDR
33
DELISTED
Alder Biopharmaceuticals
ALDR
$17.6M 0.97%
1,286,748
+162,935
+14% +$2.11M
ABMD
34
DELISTED
Abiomed Inc
ABMD
$17M 0.93%
59,389
+20,567
+53% +$6.84M
GNMK
35
DELISTED
GenMark Diagnostics, Inc
GNMK
$16.7M 0.92%
2,353,067
+353,527
+18% +$2.33M
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
$16.5M 0.91%
149,507
+7,207
+5% +$753K
LIVN icon
37
LivaNova
LIVN
$4.44B
$16.2M 0.89%
166,956
+39,446
+31% +$3.68M
DXCM icon
38
DexCom
DXCM
$29.3B
$15.6M 0.86%
524,584
+213,352
+69% +$7.5M
ZBH icon
39
Zimmer Biomet
ZBH
$17.6B
$14.7M 0.81%
118,400
+23,533
+25% +$2.67M
WBA
40
DELISTED
Walgreens Boots Alliance
WBA
$14.7M 0.81%
231,802
+9,000
+4% +$615K
QDEL icon
41
QuidelOrtho
QDEL
$1.17B
$14.6M 0.81%
223,580
+98,580
+79% +$5.96M
NKTR icon
42
Nektar Therapeutics
NKTR
$2.3B
$14.4M 0.8%
28,668
+11,254
+65% +$6.67M
AKCA
43
DELISTED
Akcea Therapeutics Inc
AKCA
$14.3M 0.79%
504,411
+46,115
+10% +$1.34M
MGNX icon
44
MacroGenics
MGNX
$291M
$14.2M 0.78%
790,305
-276,688
-26% -$4.78M
CDNA icon
45
CareDx
CDNA
$2.01B
$13.6M 0.75%
431,568
-104,920
-20% -$3.06M
ONC
46
BeOne Medicines Ltd
ONC
$33B
$13.5M 0.74%
102,200
+18,600
+22% +$2.51M
IART icon
47
Integra LifeSciences
IART
$1.5B
$12.4M 0.68%
222,350
+76,571
+53% +$3.9M
GMED icon
48
Globus Medical
GMED
$10.3B
$11.8M 0.65%
238,510
+85,479
+56% +$3.87M
OMCL icon
49
Omnicell
OMCL
$2.06B
$11.6M 0.64%
143,839
+35,797
+33% +$2.68M
TMO icon
50
Thermo Fisher Scientific
TMO
$197B
$10.6M 0.59%
38,858
+2,166
+6% +$539K
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2019 Portfolio in Review

As of Q1 2019, Bellevue Group held 155 positions worth $1.82B, up 19% from $1.52B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group deployed $80.3M of net new capital in Q1 2019, opening 17 new positions and adding to 81 existing holdings. Its largest new stake was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Celgene Corp, an estimated $56M trimmed.

  • Bellevue Group's largest Q1 2019 buy was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.
  • Bellevue Group added most to Evolent Health in Q1 2019, an estimated $21.6M increase.
  • Bellevue Group's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $56M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q1 2019, selling an estimated $3.91M.
  • Bellevue Group's ten largest holdings make up 37% of its $1.82B portfolio in Q1 2019.
  • Bellevue Group opened 17 new positions and closed 18 in Q1 2019.
  • Bellevue Group's portfolio value rose 19% quarter-over-quarter to $1.82B.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.